Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Equity Average (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Equity Average for 4 consecutive years, with $323.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 17.76% to $323.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $323.2 million, a 17.76% decrease, with the full-year FY2024 number at $318.9 million, up 11.42% from a year prior.
  • Equity Average was $323.2 million for Q3 2025 at Centessa Pharmaceuticals, down from $365.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $450.3 million in Q4 2024 to a low of $225.7 million in Q1 2024.
  • A 4-year average of $337.1 million and a median of $338.9 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 36.69% in 2023, then soared 81.72% in 2024.
  • Centessa Pharmaceuticals' Equity Average stood at $354.5 million in 2022, then tumbled by 30.1% to $247.8 million in 2023, then surged by 81.72% to $450.3 million in 2024, then decreased by 28.22% to $323.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Equity Average are $323.2 million (Q3 2025), $365.6 million (Q2 2025), and $393.9 million (Q1 2025).